FDA Flags Eye Safety Concerns as GSK Seeks Blenrep’s US Return

GSK; Blenrep; FDA; eye safety; ocular toxicity; advisory committee; multiple myeloma; drug approval; United States; relapsed/refractory multiple myeloma

FDA Launches New Priority Review Voucher Program Aligned with National Priorities

FDA; priority review voucher; CNPV; biopharma; drug approval; national priorities; accelerated review; unmet public health needs